16,500 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Purchased by Triglav Skladi D.O.O.

Triglav Skladi D.O.O. purchased a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 16,500 shares of the biotechnology company's stock, valued at approximately $1,085,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in BMRN. Norges Bank purchased a new position in shares of BioMarin Pharmaceutical in the 4th quarter worth about $234,645,000. Capital Research Global Investors raised its position in BioMarin Pharmaceutical by 23.8% during the 4th quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company's stock valued at $853,944,000 after purchasing an additional 2,496,817 shares during the last quarter. Dodge & Cox boosted its holdings in shares of BioMarin Pharmaceutical by 6.1% during the 4th quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company's stock valued at $969,270,000 after buying an additional 847,917 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of BioMarin Pharmaceutical by 114.5% during the fourth quarter. AQR Capital Management LLC now owns 1,283,599 shares of the biotechnology company's stock valued at $84,371,000 after purchasing an additional 685,099 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in BioMarin Pharmaceutical during the fourth quarter valued at $44,735,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on BMRN shares. Wedbush reissued an "outperform" rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a report on Thursday, February 20th. The Goldman Sachs Group decreased their price target on shares of BioMarin Pharmaceutical from $124.00 to $104.00 and set a "buy" rating on the stock in a research report on Monday, May 5th. Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. UBS Group raised their target price on shares of BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a "buy" rating in a research note on Thursday, February 20th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $70.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Six analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $93.45.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN traded down $0.47 during trading hours on Thursday, hitting $58.01. The stock had a trading volume of 2,436,891 shares, compared to its average volume of 1,871,771. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.62 and a current ratio of 5.33. The firm has a 50-day moving average price of $62.97 and a 200 day moving average price of $64.91. BioMarin Pharmaceutical Inc. has a fifty-two week low of $52.93 and a fifty-two week high of $94.85. The firm has a market capitalization of $11.12 billion, a price-to-earnings ratio of 26.37, a PEG ratio of 0.61 and a beta of 0.27.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. The company had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. As a group, research analysts anticipate that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Insider Activity

In other news, CAO Erin Burkhart sold 1,344 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $68.38, for a total value of $91,902.72. Following the completion of the sale, the chief accounting officer now directly owns 13,105 shares in the company, valued at $896,119.90. This represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold 4,698 shares of company stock worth $308,172 over the last three months. Insiders own 0.85% of the company's stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.